Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Association between blood omega-3 polyunsaturated fatty acids and the gut microbiota among breast cancer survivors.

Horigome A, Okubo R, Hamazaki K, Kinoshita T, Katsumata N, Uezono Y, Xiao JZ, Matsuoka YJ.

Benef Microbes. 2019 Oct 14;10(7):751-758. doi: 10.3920/BM2019.0034. Epub 2019 Sep 16.

PMID:
31965846
2.

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.

Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, Nomura H, Minami H.

Cancer Sci. 2019 Sep;110(9):2894-2904. doi: 10.1111/cas.14148. Epub 2019 Sep 3.

3.

Pubertal and Adult Testicular Functions in Nonclassic Lipoid Congenital Adrenal Hyperplasia: A Case Series and Review.

Ishii T, Hori N, Amano N, Aya M, Shibata H, Katsumata N, Hasegawa T.

J Endocr Soc. 2019 May 16;3(7):1367-1374. doi: 10.1210/js.2019-00086. eCollection 2019 Jul 1.

4.

Neonatal oral fluid as a transmission route for bifidobacteria to the infant gut immediately after birth.

Toda K, Hisata K, Satoh T, Katsumata N, Odamaki T, Mitsuyama E, Katayama T, Kuhara T, Aisaka K, Shimizu T, Xiao JZ.

Sci Rep. 2019 Jun 18;9(1):8692. doi: 10.1038/s41598-019-45198-9.

5.

Impact of chemotherapy on the association between fear of cancer recurrence and the gut microbiota in breast cancer survivors.

Okubo R, Kinoshita T, Katsumata N, Uezono Y, Xiao J, Matsuoka YJ.

Brain Behav Immun. 2019 Feb 25. pii: S0889-1591(18)31163-2. doi: 10.1016/j.bbi.2019.02.025. [Epub ahead of print]

PMID:
30818031
6.

Distinctive subpopulations of the intestinal microbiota are present in women with unexplained chronic anovulation.

Sasaki H, Kawamura K, Kawamura T, Odamaki T, Katsumata N, Xiao JZ, Suzuki N, Tanaka M.

Reprod Biomed Online. 2019 Apr;38(4):570-578. doi: 10.1016/j.rbmo.2018.12.026. Epub 2018 Dec 22.

7.

Fear of cancer recurrence among breast cancer survivors could be controlled by prudent dietary modification with polyunsaturated fatty acids.

Okubo R, Noguchi H, Hamazaki K, Sekiguchi M, Kinoshita T, Katsumata N, Narisawa T, Uezono Y, Xiao J, Matsuoka YJ.

J Affect Disord. 2019 Feb 15;245:1114-1118. doi: 10.1016/j.jad.2018.12.014. Epub 2018 Dec 10.

PMID:
30699854
8.

Reliability of Cancer Treatment Information on the Internet: Observational Study.

Ogasawara R, Katsumata N, Toyooka T, Akaishi Y, Yokoyama T, Kadokura G.

JMIR Cancer. 2018 Dec 17;4(2):e10031. doi: 10.2196/10031.

9.

Association between blood polyunsaturated fatty acid levels and depressive symptoms in breast cancer survivors.

Okubo R, Noguchi H, Hamazaki K, Sekiguchi M, Kinoshita T, Katsumata N, Narisawa T, Uezono Y, Xiao J, Matsuoka YJ.

Prostaglandins Leukot Essent Fatty Acids. 2018 Dec;139:9-13. doi: 10.1016/j.plefa.2018.11.002. Epub 2018 Nov 2.

PMID:
30471773
10.

Effect of bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: A proof-of-concept study.

Okubo R, Koga M, Katsumata N, Odamaki T, Matsuyama S, Oka M, Narita H, Hashimoto N, Kusumi I, Xiao J, Matsuoka YJ.

J Affect Disord. 2019 Feb 15;245:377-385. doi: 10.1016/j.jad.2018.11.011. Epub 2018 Nov 5.

PMID:
30423465
11.

Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurement.

Katsumata N.

Pediatr Endocrinol Rev. 2018 Sep;16(Suppl 1):28-32. doi: 10.17458/per.vol16.2018.k.standardizationmeasurementgh.

PMID:
30378780
12.

Plasma Exchange Downregulates Activated Monocytes and Restores Regulatory T Cells in Kawasaki Disease.

Koizumi K, Hoshiai M, Moriguchi T, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, Watanabe A, Harii N, Goto J, Kagami K, Abe M, Matsuda K, Sugita K.

Ther Apher Dial. 2019 Feb;23(1):92-98. doi: 10.1111/1744-9987.12754. Epub 2018 Sep 21.

PMID:
30239141
13.

Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.

Aoki Y, Ochiai K, Lim S, Aoki D, Kamiura S, Lin H, Katsumata N, Cha SD, Kim JH, Kim BG, Hirashima Y, Fujiwara K, Kim YT, Kim SM, Chung HH, Chang TC, Kamura T, Takizawa K, Takeuchi M, Kang SB.

Br J Cancer. 2018 Aug;119(5):530-537. doi: 10.1038/s41416-018-0206-7. Epub 2018 Aug 3.

14.

Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.

Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y.

Mol Pharm. 2018 Jun 4;15(6):2165-2173. doi: 10.1021/acs.molpharmaceut.8b00027. Epub 2018 May 23.

PMID:
29733658
15.

Correction to: Outcomes of plasma exchange for severe dilated cardiomyopathy in children.

Koizumi K, Hoshiai M, Moriguchi T, Toda T, Katsumata N, Kise H, Hasebe Y, Kouno Y, Goto J, Harii N, Matsuda K, Kaga S, Suzuki S, Sugita K.

Heart Vessels. 2018 Dec;33(12):1584-1585. doi: 10.1007/s00380-018-1163-z.

PMID:
29671045
16.

Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.

Koizumi K, Hoshiai M, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, Watanabe A, Kagami K, Abe M, Sugita K.

Pediatr Int. 2018 Sep;60(9):796-802. doi: 10.1111/ped.13555. Epub 2018 Jun 25.

PMID:
29543362
18.

Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.

Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T; Committee of Survey on Infliximab use for Kawasaki disease.

J Pediatr. 2018 Apr;195:115-120.e3. doi: 10.1016/j.jpeds.2017.10.013. Epub 2017 Dec 7.

PMID:
29224935
19.

[I. Current Topics of Chemotherapy for Ovarian Cancer].

Yokoyama T, Katsumata N.

Gan To Kagaku Ryoho. 2017 Feb;44(2):123-125. Japanese. No abstract available.

PMID:
28676621
20.

Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements.

Katsumata N.

Pediatr Endocrinol Rev. 2017 Mar;14 Suppl 1(Suppl 1):209-215. doi: 10.17458/per.vol14.2017.k.standardizationgrowth. Review.

PMID:
28516748
21.

Providing written information increases patient satisfaction: a web-based questionnaire survey of Japanese cancer survivors.

Sakai H, Katsumata N, Takahashi M.

Jpn J Clin Oncol. 2017 Jul 1;47(7):611-617. doi: 10.1093/jjco/hyx043.

PMID:
28369566
22.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):711-717. doi: 10.1093/annonc/mdx011.

23.

Continuing efforts to standardize measured serum growth hormone values in Japan.

Katsumata N, Shimatsu A, Tachibana K, Hizuka N, Horikawa R, Yokoya S, Tatsumi KI, Mochizuki T, Anzo M, Tanaka T.

Endocr J. 2016 Oct 29;63(10):933-936. Epub 2016 Jul 22.

24.

Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia.

Naiki Y, Miyado M, Horikawa R, Katsumata N, Onodera M, Pang S, Ogata T, Fukami M.

Endocr J. 2016 Oct 29;63(10):897-904. Epub 2016 Jul 14.

25.

High production of a class III lantipeptide AmfS in Streptomyces griseus.

Takano H, Matsui Y, Nomura J, Fujimoto M, Katsumata N, Koyama T, Mizuno I, Amano S, Shiratori-Takano H, Komatsu M, Ikeda H, Ueda K.

Biosci Biotechnol Biochem. 2017 Jan;81(1):153-164. Epub 2016 Oct 3.

PMID:
27691921
26.

NR0B1 Frameshift Mutation in a Boy with Idiopathic Central Precocious Puberty.

Shima H, Yatsuga S, Nakamura A, Sano S, Sasaki T, Katsumata N, Suzuki E, Hata K, Nakabayashi K, Momozawa Y, Kubo M, Okamura K, Kure S, Matsubara Y, Ogata T, Narumi S, Fukami M.

Sex Dev. 2016;10(4):205-209. Epub 2016 Sep 21.

PMID:
27648561
27.

SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7.

Narumi S, Amano N, Ishii T, Katsumata N, Muroya K, Adachi M, Toyoshima K, Tanaka Y, Fukuzawa R, Miyako K, Kinjo S, Ohga S, Ihara K, Inoue H, Kinjo T, Hara T, Kohno M, Yamada S, Urano H, Kitagawa Y, Tsugawa K, Higa A, Miyawaki M, Okutani T, Kizaki Z, Hamada H, Kihara M, Shiga K, Yamaguchi T, Kenmochi M, Kitajima H, Fukami M, Shimizu A, Kudoh J, Shibata S, Okano H, Miyake N, Matsumoto N, Hasegawa T.

Nat Genet. 2016 Jul;48(7):792-7. doi: 10.1038/ng.3569. Epub 2016 May 16.

PMID:
27182967
28.

Outcomes of plasma exchange for severe dilated cardiomyopathy in children.

Koizumi K, Hoshiai M, Toda T, Katsumata N, Kise H, Hasebe Y, Kouno Y, Kaga S, Suzuki S, Sugita K.

Heart Vessels. 2017 Jan;32(1):61-67. doi: 10.1007/s00380-016-0830-1. Epub 2016 Apr 27. Erratum in: Heart Vessels. 2018 Apr 18;:.

PMID:
27120173
29.

[Acute Hyperuricemia and Kidney Injury after Three Cycles of Dose-Dense Chemotherapy for Retroperitoneal Choriocarcinoma -- A Case Report].

Sakai H, Matsuda M, Kadokura G, Katsumata N.

Gan To Kagaku Ryoho. 2016 Feb;43(2):263-6. Japanese.

PMID:
27067696
30.

[Combined General and Spinal-Epidural Anesthesia under Spontaneous Breathing in a Patient with a Giant Bulla].

Tomita N, Katsumata N, Nomura M, Kurihara M, Kumakura S, Hariya S, Kakishita M, Ishikawa T, Nitanai K.

Masui. 2015 Dec;64(12):1239-41. Japanese.

PMID:
26790323
31.

Rhabdomyosarcoma of the Uterus: A Case Report.

Kuroki M, Yoneyama K, Watanabe A, Fukami T, Matsushima T, Katsumata N, Takeshita T.

J Nippon Med Sch. 2015;82(5):218-9. doi: 10.1272/jnms.82.218. No abstract available.

32.

The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study.

Harano K, Yonemori K, Hirakawa A, Shimizu C, Katsumata N, Gemma A, Fujiwara Y, Tamura K.

Breast Cancer. 2016 Sep;23(5):797-806. doi: 10.1007/s12282-015-0643-6. Epub 2015 Oct 6.

PMID:
26439379
33.
34.

Dose-dense approaches to ovarian cancer treatment.

Katsumata N.

Curr Treat Options Oncol. 2015 May;16(5):21. doi: 10.1007/s11864-015-0338-4. Review.

PMID:
25859831
35.

[Ovarian cancer: TC therapy].

Sugano T, Katsumata N.

Nihon Rinsho. 2015 Feb;73 Suppl 2:604-8. Japanese. No abstract available.

PMID:
25831831
36.

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H.

J Clin Oncol. 2015 Jul 1;33(19):2129-35. doi: 10.1200/JCO.2014.58.4391. Epub 2015 Mar 2.

PMID:
25732161
37.

Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).

Matsumoto K, Katsumata N, Shibata T, Satoh T, Saitou M, Yunokawa M, Takano T, Nakamura K, Kamura T, Konishi I.

Gynecol Oncol. 2015 Feb;136(2):218-23. doi: 10.1016/j.ygyno.2014.10.026. Epub 2014 Oct 31.

PMID:
25449313
38.

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

Sasaki Y, Miwa K, Yamashita K, Sunakawa Y, Shimada K, Ishida H, Hasegawa K, Fujiwara K, Kodaira M, Fujiwara Y, Namiki M, Matsuda M, Takeuchi Y, Katsumata N.

Invest New Drugs. 2015 Apr;33(2):332-40. doi: 10.1007/s10637-014-0180-8. Epub 2014 Nov 9.

39.

Effect of communication skills training program for oncologists based on patient preferences for communication when receiving bad news: a randomized controlled trial.

Fujimori M, Shirai Y, Asai M, Kubota K, Katsumata N, Uchitomi Y.

J Clin Oncol. 2014 Jul 10;32(20):2166-72. doi: 10.1200/JCO.2013.51.2756. Epub 2014 Jun 9.

PMID:
24912901
40.

[I. Dose-dense chemotherapy].

Katsumata N.

Gan To Kagaku Ryoho. 2014 Feb;41(2):179-83. Japanese. No abstract available.

PMID:
24826384
41.

Third-generation Aromatase Inhibitor Improved Adult Height in a Japanese Boy with Testotoxicosis.

Yoshizawa-Ogasawara A, Katsumata N, Horikawa R, Satoh M, Urakami T, Tanaka T.

Clin Pediatr Endocrinol. 2014 Apr;23(2):53-8. doi: 10.1297/cpe.23.53. Epub 2014 Apr 20.

42.

Can oncologists predict survival for patients with progressive disease after standard chemotherapies?

Taniyama TK, Hashimoto K, Katsumata N, Hirakawa A, Yonemori K, Yunokawa M, Shimizu C, Tamura K, Ando M, Fujiwara Y.

Curr Oncol. 2014 Apr;21(2):84-90. doi: 10.3747/co.21.1743.

43.

Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.

Harano K, Hirakawa A, Kato T, Suzuki K, Watanabe S, Katsumata N.

J Gynecol Oncol. 2014 Apr;25(2):124-9. doi: 10.3802/jgo.2014.25.2.124. Epub 2014 Apr 9.

44.

[Treatment of chemotherapy-induced anemia].

Kadokura G, Katsumata N.

Gan To Kagaku Ryoho. 2014 Apr;41(4):416-20. Japanese.

PMID:
24743356
45.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX.

J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17.

46.
47.

Questionnaire-based survey on chemotherapy-induced anemia.

Tanaka A, Yoshino I, Makino S, Katsumata N, Takahashi K, Kuwano H, Maehara Y, Nishiyama M.

Int J Clin Oncol. 2014;19(3):411-20. doi: 10.1007/s10147-014-0677-3. Epub 2014 Mar 8.

PMID:
24610155
48.

Satisfying the needs of Japanese cancer patients: a comparative study of detailed and standard informed consent documents.

Sato K, Watanabe T, Katsumata N, Sato T, Ohashi Y.

Clin Trials. 2014 Feb;11(1):86-95. doi: 10.1177/1740774513515550. Epub 2014 Jan 9.

PMID:
24408900
49.

Two novel HSD3B2 missense mutations with diverse residual enzymatic activities for Δ5-steroids.

Takasawa K, Ono M, Hijikata A, Matsubara Y, Katsumata N, Takagi M, Morio T, Ohara O, Kashimada K, Mizutani S.

Clin Endocrinol (Oxf). 2014 Jun;80(6):782-9. doi: 10.1111/cen.12394. Epub 2014 Jan 16.

PMID:
24372086
50.

Supplemental Content

Loading ...
Support Center